Clinical Trial

A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A multicenter, single-arm Phase II study to evaluate the efficacy and safety of fulzerasib (IBI351) in combination with ivonescimab (AK-112) in first-line treatment of advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation
Trial Details
NCT Number NCT06936644
Lead Sponsor Shanghai Chest Hospital
Collaborators: Innovent Biologics, Inc., Akesobio
Conditions KRAS G12C Lung Cancer
Enrollment 39 participants
Start Date 2025-04-30
Primary Completion 2027-04-30 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-20